Interleukin‐1 in multiple myeloma: producer cells and their role in the control of IL‐6 production
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
We studied the role of interleukin (IL)‐1β in patients with multiple myeloma. By in situ hybridization and immunochemistry, myeloid and megakaryocytic cells expressed high levels of the IL‐1β gene and produced IL‐1β. Myeloma cells less potently expressed the IL‐1β gene and IL‐1β protein. IL‐1β gene expression was not constitutive since it was detected in the bone marrow myeloma cells of two patients, unlike circulating tumoural cells. In addition, nine myeloma cell lines failed to express the IL‐1β gene and this expression could not be induced by 12 different cytokines. We demonstrated that IL‐1 was mainly responsible for IL‐6 production in the tumoural environment through a PGE 2 loop. In fact, an IL‐1 receptor antagonist (IL‐1RA) blocked PGE 2 synthesis and IL‐6 production by 80%; this blockage could be reversed by adding synthetic PGE 2. Similar findings were found with indomethacin, an inhibitor of cyclooxygenase that blocks PGE 2 synthesis. Taken together, these data emphasize the possibility of blocking IL‐1 by using IL‐1RA or other antagonists in order to block IL‐6 production, which is a major tumoural survival and proliferation factor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., et al. (1988) · Nature · doi:10.1038/332083a0 · Cited by 1,633 · cited 3×
“Myeloma cells may produce IL-6 weakly in vivo or in vitro (Kawano et al, 1988; Hata et al, 1993; Levy et al, 1991; Schwab et al, 1991).”
BackgroundInterleukin-6 is a prognostic factor in multiple myeloma [letter] [see comments]
Ludwig, H., Nachbaur, D., Fritz, E., Krainer, M., & Huber, H. (1991) · Blood · doi:10.1182/blood.v77.12.2794.2794 · Cited by 158 · cited 2×
“…relevant, since several studies have shown that patients with overproduction of IL-6 and high serum CRP levels are poor responders to conventional chemotherapy or to high-dose chemotherapy and autologous stem cell transplantation (Ludwig et al, 1991; Bataille et al, 1992; Vesole et al, 1996).”
Background
Cited by
Multiple myeloma: evolving genetic events and host interactions
Kuehl, W. M., & Bergsagel, P. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc746 · Cited by 818
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
Quach, H., Ritchie, D., Stewart, A. K., Neeson, P., Harrison, S., Smyth, M. J., & Prince, H. M. (2010) · Leukemia · doi:10.1038/leu.2009.236 · Cited by 600
Interleukin-1 Beta—A Friend or Foe in Malignancies?
Bent, R., Moll, L., Grabbe, S., & Bros, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082155 · Cited by 444
Bone marrow mesenchymal stem cells are abnormal in multiple myeloma
Corre, J., Mahtouk, K., Attal, M., Gadelorge, M., Huynh, A., Fleury-Cappellesso, S., Danho, C., Laharrague, P., Klein, B., Rème, T., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404621 · Cited by 328
Self-citationBiology of Osteoclast Activation in Cancer
Roodman, G. D. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.15.3562 · Cited by 306
Metadata
- Authors
- Costes, V., Portier, M., Lu, Z., Rossi, J., Bataille, R., & Klein, B.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 1998-12
- Volume
- 103
- Issue
- 4
- Pages
- 1152-1160
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W1970929570
- Cited by
- 87
- References
- 2
- FWCI
- 1.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interleukin‐1 in multiple myeloma: producer cells and their role in the control of IL‐6 production. https://app.cochat.ai/papers/10.1046/j.1365-2141.1998.01101.x
- The paper
- Costes, V., Portier, M., Lu, Z., Rossi, J., Bataille, R., & Klein, B. (1998). Interleukin‐1 in multiple myeloma: producer cells and their role in the control of IL‐6 production. British Journal of Haematology. https://doi.org/10.1046/j.1365-2141.1998.01101.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.